ArticleFrontiers in public health2025
Migration-adjusted prostate cancer incidence in China: a population-based epidemiological analysis.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explainable machine learning model for in-hospital hypoglycemia risk in patients with latent autoimmune diabetes in adults.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: China's internal migration poses major challenges to cancer surveillance systems that rely on household-registered populations (HRP). Excluding migrants can lead to biased incidence estimates and misinformed public health planning. Methods: This study estimated the prostate cancer incidence among the resident population (RP) using a Bayesian integrated nested Laplace approximation with stochastic partial differential equation (INLA-SPDE) model, incorporating inter-provincial migrant weights, and explored spatial clustering. Results: The findings revealed a substantial interprovincial migrant population of 73,459,708 individuals, based on data from the 2016 China Migrants Dynamic Survey conducted by the Migrant Population Service Center, National Health Commission of China. With Shanghai and Beijing showing relatively high difference proportions of 40.7 and 37.9%, respectively. Nationally, the differences in estimated incidence between RP and HRP were substantial, ranging from 1.1/100,000 in Guizhou (HRP 5.4/100,000, RP 6.5/100,000) to -9.9/100,000 in Shanghai (HRP 27.6/100,000, RP 17.7/100,000). The analysis estimated that the provinces with the largest differences between incident cases among RP and HRP were Guangdong (469 cases, 9.7% relative to HRP cases) and Jiangsu (305 cases, 6.2% relative to HRP cases). Inflow provinces tended to have their cases underestimated and their incidence overestimated, whereas the opposite pattern was observed in outflow provinces. Incidence exhibits significant spatial clustering, with higher incidence in eastern coastal metropolitan areas and lower incidence in central-western regions and northeastern parts. Conclusion: Migration substantially influences prostate cancer incidence surveillance in China. Incorporating migrant-adjusted estimates provides a more accurate representation of disease burden, supports equitable allocation of healthcare resources, and offers methodological guidance for improving cancer registration systems in regions with high population mobility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.